# Ultrasound Imaging Properties of Heterologously Synthesized Gas Vesicles from Halophilic Archaeon

## TL;DR

Researchers created gas vesicles in a different archaeon to improve ultrasound imaging, showing they work as well as natural ones.

## Contribution

A heterologous system for producing functional gas vesicles from Halobacterium in Haloferax volcanii is developed.

## Key findings

- Heterologously synthesized GVvol showed similar in vitro signal intensity to natural GVs.
- GVvol achieved comparable in vivo ultrasound signal intensity in the kidney to natural GVs.
- The study confirms the functional integrity of heterologously synthesized gas vesicles.

## Abstract

Biosynthetic gas vesicles (GVs), as novel nanoscale ultrasound contrast agents, exhibit unique potential in biomedical ultrasound imaging. For example, they are expected to have better tissue penetration through the tumor vasculature for detecting tumor cells by the design of GV-based acoustic probes. Of all these GVs, GVs from Halobacterium sp. NRC-1 possess the largest size (over 200 nm) and are nearly spherical in shape, endowing them with stronger acoustic signals and better tumor penetration. However, their genetic manipulation is relatively difficult due to the requirement of a high-salt cytoplasmic environment for their expression and assembly, limiting the application of biosynthetic technology for modulating their structural features in heterologous host cells. In this study, we cloned the gene cluster encoding GVs from Halobacterium sp. NRC-1 and transformed it into Haloferax volcanii, an archaeal species naturally incapable of producing GVs. The genetically engineered Haloferax volcanii successfully synthesized functional GVs (GVvol) with a similar size and shape to naturally synthesized GVs from Halobacterium sp. NRC-1 (GVhalo). The ultrasound imaging properties of GVvol heterologously synthesized in Haloferax volcanii were compared with naturally synthesized GVhalo in vitro and in vivo, showing that GVvol could achieve a mean signal intensity of 113.6 ± 0.9 a.u. in vitro and a peak intensity of 121.5 ± 0.8 a.u. in vivo in the kidney, compared with 115.7 ± 0.5 a.u. and 119.0 ± 0.5 a.u. for GVhalo, respectively. These findings confirm the functional integrity of heterologously synthesized GVvol and its potential for biomedical applications. Our study provides a solid experimental foundation for genetically tailoring Halobacterium GV properties to optimize biomedical imaging performance.